-
平臺(tái)編號(hào)：bio-137359
-
國(guó)際編號(hào)：DSM 17217
-
拉丁屬名： Veillonella montpellierensis
-
規(guī)格：培養(yǎng)物/凍干粉
-
用途：DSM 原裝進(jìn)口
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu) 說(shuō)明書(shū)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
Veillonella montpellierensis
Veillonella montpellierensis
DSM 17217
BACTERIA
How to read the following data (Example)
Name:
Veillonella montpellierensis Jumas-Bilak et al. 2004
DSM No.:
17217, Type strain
Strain designation:
ADV 281.99, AIP 299.01
Other collection no.
or WDCM no.:
CCUG 48299,CIP 107992
Isolated from:
human,gastric fluid of a newborn
Country:
France
Montpellier
Date of sampling:
1999
Nagoya Protocol Restrictions:
France requires a benefit-sharing declaration for French genetic resources at the time of utilization, i.e., conducting research. France considers access to genetic resources when utilization begins and not when the initial collection of the material took place and applies to material both in-situ and ex-situ and users within and outside of France.
To comply with French law, you, the user need to make a Declaration regarding access to genetic resources and benefit-sharing arising from your non-commercial utilisation of genetic resources. The steps are the following:
1. File a declaration via the CERFA form n. 15786 (https://www.formulaires.service-public.fr/gf/getAnnexe.do?cerfaAnnexe=1&cerfaFormulaire=15786*02) or by electronic procedure (https://www.demarches-simplifiees.fr/commencer/apa-declaration-pmorale)
2. Await approval by the Ministry for the Ecological Transition, the competent national authority
3. Respond to any requests for more information from the competent national authority
4. Receive an acknowledgment of receipt by the competent national authority certifying the prior informed consent (PIC) and establishment of mutually agreed terms (MAT) regarding benefit-sharing. This procedure shall not exceed 2 months.
For more information about this topic please see the Access and Benefit-Sharing Clearing House: https://absch.cbd.int/en/countries/FR
For more information about the commercial use of this genetic resources please contact: justiziariat@dsmz.de
History:
<- CCUG <-J.P.Carlier, AIP 299.01 <- CHU Montpellier, ADV 281.99
Cultivation conditions:
Medium 104 + 10µl/ml putrescine (0.03%) + 10 µl/ml sodium lactate (50%), anaerobic, 37°C
Please follow special instructions: 'Cultivation of Anaerobes'
Complete DSMZ Media List
Summary and
additional information:
<- CCUG <-J.P.Carlier, AIP 299.01 <- CHU Montpellier, ADV 281.99. Human,gastric fluid of a newborn; France, Montpellier. Type strain. Taxonomy/description (9338). (Medium 104 + 10µl/ml putrescine (0.03%) + 10 µl/ml sodium lactate (50%), 37°C, anaerobic)
Literature:
9338
Risk group:
1 (+) (classification according to German TRBA)
Supplied as:
Delivery form Prices
